-
SABCS China Voice | Professors Yan Min & Lü Huimin: U-BOMB-HER Study Advances Treatment of HER2-Positive Brain Metastases
PS5-01-13 — Utidelone Plus Bevacizumab for the Treatment of HER2-Positive Breast Cancer Brain Metastases (U-BOMB-HER): A Multicenter, Single-Arm Phase II Study Study Overview Background Although novel HER2-targeted agents, including tyrosine…
-
SABCS China Voice | Professor Yan Min’s Team: Post-PERMEATE Study Clarifies Radiotherapy Timing in HER2-Positive Brain Metastases
Editor’s Note: HER2-positive breast cancer has a high incidence of brain metastases. In the era when treatment relied primarily on local therapies, patient survival outcomes were poor. The PERMEATE study…
-
ASH Global Perspectives | Prof. Hanny Al-Samkari: Efficacy, Safety, and Dose Optimization of Ianalumab + Eltrombopag in Second-Line ITP
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder, and management after failure of first-line corticosteroid therapy remains a significant clinical challenge. In recent years, emerging therapies targeting key pathways involved…
-
ASH Global Perspectives | Professor Jeff Sharman: How Can We Reshape Treatment Strategies for Elderly Patients With DLBCL?
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of lymphoma, but its management is particularly challenging in elderly patients. Standard R-CHOP chemotherapy is often poorly tolerated in…
-
ASH Global Perspectives | Prof. Fabio Efficace’s Team: Advances in Patient-Reported Outcomes in Hematology
In recent years, the field of hematologic malignancies has advanced at an unprecedented pace, with a steady emergence of novel therapies. While prolonging survival remains a central goal, patients’ quality…
-
New Breakthrough in Targeting BAFF Pathway: Ianalumab Significantly Prolongs Time to Treatment Failure in ITP Patients — A Detailed Look at VAYHIT 2
At the recently concluded American Society of Hematology (ASH) Annual Meeting in 2025, Dr. Hanny Al-Samkari from Massachusetts General Hospital presented the highly anticipated primary analysis of the VAYHIT 2 study. Presented as a Late-Breaking Abstract (LBA), this global, randomized, double-blind, Phase 3 clinical trial evaluated the efficacy and safety of combining the novel BAFF…
-
Breaking Diagnostic Bottlenecks: The IBMDX Study Reveals 37% Diagnostic Yield and Health Economic Value of Whole Genome Sequencing (WGS) in Inherited Bone Marrow Failure Syndromes
At the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. Lucy Fox from the Peter MacCallum Cancer Centre (Australia) presented the highly anticipated results of the IBMDX study. This landmark trial evaluated the clinical utility and economic impact of “Upfront Whole Genome Sequencing (WGS)” in patients with suspected Inherited Bone Marrow Failure Syndromes (IBMFS).…
-
HR of 0.17! Tech-Dara: A Potent BCMA/CD38 Dual-Targeting Immunotherapy Combination Leads a New Paradigm in Second-Line MM Treatment—MAJEStec-3 Study Heavily Released
At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. María-Victoria Mateos, representing the research team, unveiled the highly anticipated results of the MAJEStec-3 study. This marks the first reported Phase III clinical trial of a BCMA-targeted bispecific antibody. Comparing the combination of Teclistamab and Daratumumab (“Tech-Dara”) against…
Connecting Medical Expertise through Media